Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.42 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
| ▸ | GABRD | O14764 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2435779 | 1.00 | APLNR (0.46) | APLNRLMNACYP2C19GRM2GRM3 | |
| SCHEMBL2435778 | 1.00 | APLNR (0.46) | APLNRLMNACYP2C19GRM2GRM3 | |
| SCHEMBL25527583 | 0.86 | CYP2C19 (0.48) | APLNRLMNACYP2C19GRM2GRM3 | |
| SCHEMBL4443561 | 0.80 | APLNR (0.56) | APLNRLMNACYP2C19GRM2GRM3 | |
| SCHEMBL18199 | 0.80 | TSHR (0.45) | APLNRLMNACYP2C19GRM2GRM3 | |
| SCHEMBL2433841 | 0.79 | SMN1; SMN2 (0.30) | APLNRSMN1; SMN2 | |
| SCHEMBL2433838 | 0.79 | SMN1; SMN2 (0.30) | APLNRSMN1; SMN2 | |
| SCHEMBL19386548 | 0.79 | SMN1; SMN2 (0.41) | LMNACYP2C19GRM2GRM3GRM4 | |
| SCHEMBL2433836 | 0.79 | SMN1; SMN2 (0.30) | APLNRSMN1; SMN2 | |
| SCHEMBL321916 | 0.78 | APLNR (0.48) | APLNRLMNACYP2C19GRM2GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189054-B1 | (1-FLUORO-CYCLOHEX-1-YL)-ETHYL SUBSTITUTED DIAZA- AND TRIAZA-TRICYCLIC COMPOUNDS AS INDOLE-AMINE-2,3-DIOXYGENASE (IDO) ANTAGONISTS FOR THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2019-07-24 | — | — | EP | disclosed |
| US-20170355703-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE | MERCK PATENT GMBH (DE) | 2017-12-14 | — | — | US | disclosed |
| US-9771370-B2 | Compounds for the inhibition of indoleamine-2,3-dioxygenase | MERCK PATENT GMBH (DE) | 2017-09-26 | — | — | US | disclosed |
| EP-2086966-B1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355703-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE | IDO1, IDO2, INMT | APLNR 1500/4885LMNA 4830/4885CYP2C19 1419/4885 |
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | EIF2AK2, HAVCR2, GTF3C2 | APLNR 4829/4885LMNA 4420/4885CYP2C19 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.